Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Strategies to Manage Hepatitis C Virus Infection Disease Burden - Volume 3 Publisher Pubmed



Alfaleh FZ1 ; Nugrahini N2 ; Maticic M3 ; Tolmane I4, 5 ; Alzaabi M6 ; Hajarizadeh B7, 8 ; Valantinas J9 ; Kim DY10 ; Hunyady B11, 12 ; Abaalkhail F13 ; Abbas Z14 ; Abdou A15 ; Abourached A16 ; Al Braiki F17 Show All Authors
Authors
  1. Alfaleh FZ1
  2. Nugrahini N2
  3. Maticic M3
  4. Tolmane I4, 5
  5. Alzaabi M6
  6. Hajarizadeh B7, 8
  7. Valantinas J9
  8. Kim DY10
  9. Hunyady B11, 12
  10. Abaalkhail F13
  11. Abbas Z14
  12. Abdou A15
  13. Abourached A16
  14. Al Braiki F17
  15. Al Hosani F18
  16. Al Jaberi K19
  17. Al Khatry M20
  18. Al Mulla MA18
  19. Al Quraishi H21
  20. Al Rifai A22
  21. Al Serkal Y23
  22. Alam A24
  23. Alashgar HI25
  24. Alavian SM26, 27
  25. Alawadhi S15
  26. Aldabal L28
  27. Aldins P29
  28. Alghamdi AS30
  29. Alhakeem R31
  30. Aljumah AA32
  31. Almessabi A17
  32. Alqutub AN30
  33. Alswat KA33
  34. Altraif I32
  35. Andrea N34
  36. Assiri AM31
  37. Babatin MA30
  38. Baqir A35
  39. Barakat MT36
  40. Bergmann OM37
  41. Bizri AR38
  42. Chaudhry A39
  43. Choi MS40
  44. Diab T41
  45. Djauzi S42
  46. El Hassan ES15
  47. El Khoury S43
  48. Estes C44
  49. Fakhry S45
  50. Farooqi JI46, 47
  51. Fridjonsdottir H48, 58, 59
  52. Gani RA42
  53. Ghafoor Khan A49
  54. Gheorghe L50
  55. Goldis A51
  56. Gottfredsson M52
  57. Gregorcic S3
  58. Gunter J44
  59. Hamid S53
  60. Han KH10
  61. Hasan I42
  62. Hashim A54
  63. Horvath G55
  64. Husni R56
  65. Jafri W57
  66. Jeruma A4, 5
  67. Jonasson JG48, 58, 59
  68. Karlsdottir B60
  69. Kim YS61
  70. Koutoubi Z62
  71. Lesmana LA42, 63
  72. Liakina V9, 64
  73. Lim YS65
  74. Love A52, 66
  75. Maimets M67
  76. Makara M68
  77. Malekzadeh R69
  78. Memon MS70
  79. Merat S69
  80. Mokhbat JE71
  81. Mourad FH72
  82. Muljono DH73, 74
  83. Nawaz A75
  84. Olafsson S37
  85. Priohutomo S76
  86. Qureshi H77
  87. Rassam P43
  88. Razavi H44
  89. Razavishearer D44
  90. Razavishearer K44
  91. Rozentale B4
  92. Sadik M70
  93. Saeed K78
  94. Salamat A79
  95. Salupere R67
  96. Sanai FM1
  97. Sanityoso Sulaiman A42
  98. Sayegh RA80
  99. Schmelzer JD44
  100. Sharara AI72
  101. Sibley A44
  102. Siddiq M81, 82, 83
  103. Siddiqui AM83
  104. Sigmundsdottir G84, 85
  105. Sigurdardottir B60
  106. Speiciene D9
  107. Sulaiman A42, 86
  108. Sultan MA86
  109. Taha M87
  110. Tanaka J88
  111. Tarifi H89
  112. Tayyab G90, 91
  113. Ud Din M92
  114. Umar M93, 94
  115. Videcnikzorman J3
  116. Yaghi C80, 81
  117. Yunihastuti E95
  118. Yusuf MA96
  119. Zuberi BF97
  120. Blach S44

Source: Journal of Viral Hepatitis Published:2015


Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995). © 2015 John Wiley & Sons Ltd.
Other Related Docs